Skye Bioscience soars after experimental weight-loss drug shows promise in mice

Skye Bioscience

15/04/2025 15:32

Updates

** Shares of drug developer Skye Bioscience SKYE.O rise as much as 185% to a near three-month high of $3.73; last up 65.3% in morning trade

** Stock is set for its best day in over a year, if gains hold

** Co says its drug candidate, nimacimab, showed 23.5% weight loss in mice, comparable to Eli Lilly's LLY.N popular drug, tirzepatide, sold as Zepbound, and Novo Nordisk's NOVOb.CO experimental drug, monlunabant

** SKYE also says nimacimab, when combined with tirzepatide, showed a greater than 30% weight loss

** Initial data from SKYE's mid-stage study in obesity is expected in late Q3/early Q4 2025

** Including session's move, stock down 23% YTD

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))